AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

AbbVie (ABBV) has reported Asset Writedowns and Impairment for 4 consecutive years, with $4.5 billion the latest figure, recorded in Q4 2024.

• On a quarterly basis, Asset Writedowns and Impairment rose 218.58% year-over-year to $4.5 billion in Q4 2024; TTM through Dec 2025 was $4.5 billion, a 0.0% change from a year earlier, with the FY2025 full-year figure at $847.0 million, down 81.08% from the prior year.
• Asset Writedowns and Impairment was $4.5 billion for Q4 2024 at AbbVie, up from $1.4 billion in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $4.5 billion in Q4 2024 and troughed at $710.0 million in Q1 2023.
• A 3-year average of $1.9 billion and a median of $1.4 billion in 2023 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment surged 174.55% in 2023 and soared 218.58% in 2024, its largest moves.
• Over 3 years, Asset Writedowns and Impairment stood at $770.0 million in 2022, then jumped by 82.47% to $1.4 billion in 2023, then soared by 218.58% to $4.5 billion in 2024.
• The last three Asset Writedowns and Impairment figures came in at $4.5 billion (Q4 2024), $1.4 billion (Q4 2023), and $2.1 billion (Q3 2023), per Business Quant data.